Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 13/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.47 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12954377 | 0.92 | GSK3B (0.55) | GSK3BCHEK1CDK2CCNE1 | |
| SCHEMBL13119192 | 0.91 | GSK3B (0.65) | GSK3BCDK2CCNE1 | |
| SCHEMBL14418925 | 0.91 | GSK3B (0.53) | GSK3BCHEK1CDK2CCNE1CCNA2 | |
| SCHEMBL14418651 | 0.89 | GSK3B (0.55) | GSK3BCHEK1SMN1; SMN2CDK2CCNE1 | |
| SCHEMBL14607246 | 0.88 | GSK3B (0.53) | GSK3BCHEK1MAP3K12ALDH1A1CDK2 | |
| SCHEMBL14545947 | 0.87 | GSK3B (0.56) | GSK3BCHEK1CDK2CCNE1 | |
| SCHEMBL14545949 | 0.86 | GSK3B (0.60) | GSK3BCHEK1CDK2CCNE1 | |
| SCHEMBL14418650 | 0.85 | GSK3B (0.61) | GSK3BCHEK1ALDH1A1CDK2CCNE1 | |
| SCHEMBL14545952 | 0.85 | GSK3B (0.52) | GSK3BCHEK1CDK2CCNE1CCNA2 | |
| SCHEMBL12954408 | 0.84 | GSK3B (0.51) | GSK3BCHEK1MAP3K12CDK2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007044449-A2 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |